David Raben, Chief Medical Officer at Bicara Therapeutics Inc. (BCAX), sold 15,594 shares at $18.45 ($292K) on 2025-11-24, disclosed to the SEC on 2025-11-25.
Scheduled sale ($292k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.45 | 5,500 | $101K | 34.8% |
| 2 | $18.84 | 906 | $17K | 5.9% |
| 3 | $18.84 | 4,594 | $87K | 29.7% |
| 4 | $18.84 | 4,594 | $87K | 29.7% |
| Total | $18.70 avg | 15,594 | $292K | 100% |
| Filing → |
| BCAX | SELL | 2026-03-05 | $607K | — | Filing → |
| BCAX | SELL | 2025-10-10 | $406K | — | Filing → |